Jacob Rotmensch to Protein Kinase Inhibitors
This is a "connection" page, showing publications Jacob Rotmensch has written about Protein Kinase Inhibitors.
Connection Strength
0.233
-
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep; 138(3):507-12.
Score: 0.117
-
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):30-5.
Score: 0.115